Skip survey header

Adherence to Oral Oncolytics - Pre-Test

The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics

A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.

This activity is supported by unrestricted educational grants from AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceutical Corporation; and Taiho Oncology, Inc. 

Release date: December 8, 2017                        
Expiration date: December 7, 2018
Estimated time to complete activity: 1.0 hour


Moderator: Kimberly Hicks, PharmD, MHA

Diane Cope, PhD, ARNP, BC, AOCNP
Florida Cancer Specialists, Fort Myers, FL

Susan Scherer, RN, BSN, OCN
RN Cancer Guides Solutions, Tampa, FL

John Novak, CHA, PA-C
Rocky Mountain Cancer Centers, Aurora, CO

Activity Rationale and Purpose
The issue of patient adherence to oral medications as part of cancer treatment regimens continues to evolve in importance in the US. Almost 40% of the total cost of targeted therapies in the US are now for oral formulations, up from 26% in 2010. Within a busy oncology practice, there is often a lack of dedicated resources to devote to following up with patients about sticking with their oral treatment plans, assessing patients who may be at risk for not taking oral treatments as prescribed, or advocating for co-pays or other financial resources available to patients. Advanced Practitioners in oncology are well-positioned to intervene and make a significant difference in motivating patients to continue their oral treatment regimens. This education will focus on how APs can overcome a variety of barriers for patient non-adherence to oral therapies and encourage patients to continue their regimens.

Intended Audience
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.

Learning Objectives
After completing this educational activity, participants should be able to:
• Demonstrate an increased understanding of the potential adherence barriers for patients whose treatment regimens include an oral medication
• Describe the role of various stakeholders who practice collaboratively to assess patients at high risk for nonadherence with their oral cancer medications
• Develop a strategy for advanced practitioners for improving patient adherence with oral oncology medications in their own practice
• Counsel and educate patients on appropriate resources available for medication copayments

Continuing Education


The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®)

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

A maximum of 1.0 contact hours may be earned for successful completion of this activity.


This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-9999-17-101-H01-P. This program is designated for up to 1.0 contact hours (0.10 CEUs) of continuing pharmacy educational credit.

Financial Disclosures
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Dr. Hicks has nothing to disclose.
Dr. Cope has nothing to disclose.
Ms. Scherer has nothing to disclose.
Mr. Novak has served as a consultant for bioTheranostics, and served on speakers’ bureaus for Amgen and Pfizer.

Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

Chris Cherry has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.

Content Reviews
Kate D. Jeffers, PharmD, BCOP, has nothing to disclose.
Carol Blecher, RN, MS, AOCN, APNC, CBPN-C, CBCN, has nothing to disclose.

Annenberg Center for Health Sciences at Eisenhower
John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Harborside Medical Education, and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Harborside Medical Education of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit
To claim credit for this activity, participants must complete the pre-assessment, view the content, pass the post-assessment, and complete and submit an evaluation. Content is available on

Statement of Credit: Participants who successfully complete this activity (including scoring 70% on the learning assessment and complete and submit the evaluation form) will be able to download a statement of credit.